Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8603-8612

  Post, Dawn E ^a,b   Devi, Narra Sarojini ^a,b   Li, Zhenchao ^a,b   Brat, Daniel J ^b   Kaur, Balveen ^a,b   Nicholson, Ainsley ^a,b   Olson, Jeffrey J ^b   Zhang, Zhaobin ^b   Van Meir, Erwin G ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; E1A PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ONCOLYTIC VIRUS; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ADENOVIRUS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIA DEPENDENT ADENOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CELL HYPOXIA; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 11144229120     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1432     Document Type: Article

References (34)

1. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62.
2. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond) 1996;379:88-91.
3. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
4. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 down-regulated by von Hippel-Lindau tumour suppressor pVHL. Nature (Lond) 2003;425:307-11.
5. Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc. Natl Acad Sci USA 2001;98:14748-50.
6. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer (Phila) 2000;88:2606-18.
7. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
8. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92.
9. Brat DJ, Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 2003;8:d100-16.
10. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Investig 2004;84:397-405.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
12. Safran M, Kaelin WG, Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Investig 2003;111:779-83.
13. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-312.
14. Fulci G, Chiocca EA. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci 2003;8:e346-60.
15. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 2003;8:d577-88.
16. Haviv YS, Curiel DT. Engineering regulatory elements for conditionally-replicative adeno- viruses. Curr Gene Ther 2003;3:357-85.
17. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004;4:41-51.
18. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22:2065-72.
19. Cuevas Y, Hernandez-Alcoceba R, Aragones J, et al. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 2003;63:6877-84.
20. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
21. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-7.
22. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 d1309. Virus Res 1995;39:75-82.
23. Van Meir EG. Identification of nude mice in tumorigenicity assays. Int J Cancer 1997;71:310.
24. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58:5738-48.
25. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16.
26. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash DC) 1996;274:373-6.
27. Marcantonio D, Panasci LC, Hollingshead MG, et al. 2-Chloroethyl-3- sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res 1997;57:3895-8.
28. Chen ZP, Wang G, Huang Q, et al. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neurooncol 1999;44:7-14.
29. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
30. Cruickshank GS, Rampling RP, Cowans W. Direct measurement of the PO2 distribution in human malignant brain tumours. Adv Exp. Med Biol 1994;345:465-70.
31. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003;14:425-33.
32. Gandara DR, Lara PN Jr., Goldberg Z, et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002;29:102-9.
33. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001;98:15155-60.
34. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;14:1983-91.